Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01912456 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema
A Phase 3 study of Hereditary Angioedema Types I and II, sponsored by CSL Behring.
- Completed
- Registry status
- Phase 3
- Development phase
- 90
- Enrollment target
- 20
- Study locations
NCT01912456: Completed Phase 3 study of Hereditary Angioedema Types I and II, sponsored by CSL Behring.
NCT01912456 is a Phase 3 study of Hereditary Angioedema Types I and II that has completed, run by CSL Behring. The registered enrollment target is 90 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01912456, a Phase 3 study of Hereditary Angioedema Types I and II, has completed, sponsored by CSL Behring.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 90 participants
- Enrollment target
- 20
- Study locations
Study Summary
The aim of this study is to assess the efficacy of C1-esterase inhibitor in preventing hereditary angioedema attacks when it is administered under the skin of subjects with hereditary angioedema. The safety of C1-esterase inhibitor will also be assessed. Each subject will enter a run-in period of up to 8-weeks. Subjects who complete the run-in period and who are eligible will then enter the treatment phase which comprises two sequential treatment periods. In the treatment phase, subjects will be randomized to one of four arms consisting of treatment with low- or higher-volume C1-esterase inhibitor in one treatment period and treatment with low- or higher-volume placebo in the other treatment period. The study will measure the number of hereditary angioedema attacks that subjects experience while receiving each treatment.
Primary Outcome
The time normalized number of HAE attacks as reported by the investigator per subject was calculated as: The total number of HAE attacks per subject and per treatment period / length of stay of subject in treatment period (days), Where length of stay of subject in treatment period was calculated as: Date of last day of subject in treatment period - date of first day of Week 3 of subject in treatment period + 1.
Conditions Studied
Interventions
- BIOLOGICAL Low-volume C1-esterase inhibitor
- BIOLOGICAL Higher-volume C1-esterase inhibitor
- BIOLOGICAL Low-volume placebo
- BIOLOGICAL Higher-volume placebo
Study Locations (20)
California
- Study Site - Bell Gardens
- Study Site - La Jolla
- Study Site - Orange
- Study Site - Walnut Creek
Ohio
- Study Site - Cincinnati
- Study Site - Columbus
- Study Site - Toledo
Virginia
- Study Site - Richmond
- Study Site - Virginia Beach
Alabama
- Study Site - Birmingham
Arizona
- Study Site - Scottsdale
Colorado
- Study Site - Colorado Springs
Maryland
- Study Site - Chevy Chase
Massachusetts
- Study Site - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2014-01 |
| Est. Completion | 2015-10 |
| Phase | Phase 3 |
What the finished NCT01912456 record still lists
NCT01912456 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower).
The record links to 1 condition, with Hereditary Angioedema Types I and II appearing as the primary indexed condition, and to 4 interventions - of which Low-volume C1-esterase inhibitor is the first listed.
NCT01912456 names 20 study sites across 14 states, led by California, Ohio, Virginia.
Frequently Asked Questions
What is clinical trial NCT01912456 about?
NCT01912456 is a clinical study titled "A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema". The aim of this study is to assess the efficacy of C1-esterase inhibitor in preventing hereditary angioedema attacks when it is administered under the skin of subjects with hereditary angioedema. The safety of C1-esterase inhibitor will also be assessed. Each subject will enter a run-in period of up...
What is the current status of trial NCT01912456?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2014-01. Estimated completion is 2015-10.
What conditions does trial NCT01912456 study?
This clinical trial studies the following conditions: Hereditary Angioedema Types I and II.
What interventions are being tested in trial NCT01912456?
The interventions under investigation include: Low-volume C1-esterase inhibitor (BIOLOGICAL), Higher-volume C1-esterase inhibitor (BIOLOGICAL), Low-volume placebo (BIOLOGICAL), Higher-volume placebo (BIOLOGICAL).
Who is sponsoring clinical trial NCT01912456?
This trial is sponsored by CSL Behring, which has 71 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01912456 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Angioedema Types I and II
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01912456's enrollment target sits among peer trials
90 1724th of 2000 higher than 263 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia